title: Clinical utility of orally disintegrating olanzapine in Chinese patients with schizophrenia: a review of effectiveness, patient preference, adherence, and other properties.
abstract: The primary objective of this systematic review was to examine the evidence for the efficacy, effectiveness, and safety of orally disintegrating olanzapine in Chinese populations. A systematic literature search was conducted using databases covering international and Chinese journals, ClinicalTrials.gov, and internal and external trial registries at Eli Lilly and Company using search terms related to target countries (People's Republic of China, Hong Kong, and Taiwan) and orally disintegrating olanzapine treatment. A publication and one clinical study report were retrieved. The clinical study showed orally disintegrating olanzapine and the standard oral tablet to have similar efficacy and tolerability profiles. A bioequivalence study has shown that orally disintegrating olanzapine and the standard oral tablet have similar pharmacokinetic profiles. Orally disintegrating olanzapine and the standard oral tablet have similar efficacy and tolerability profiles.
authors.affiliation: Mental Health Institute of The Second Xiangya Hospital, Hunan Province Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, People's Republic of China.
authors.forename: Jingping
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Mental Health Institute of The Second Xiangya Hospital, Hunan Province Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, People's Republic of China.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Ou
authors.affiliation: Lilly Suzhou Pharmaceutical Co, Ltd, Jiangsu, People's Republic of China.
authors.forename: Haibo
authors.initials: H
authors.lastname: Xue
authors.affiliation: Lilly Suzhou Pharmaceutical Co, Ltd, Jiangsu, People's Republic of China.
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.affiliation: Global Health Outcomes, Eli Lilly and Company, Sydney, Australia.
authors.forename: William
authors.initials: W
authors.lastname: Montgomery
authors.affiliation: Emerging Markets Business Unit (Neuroscience), Eli Lilly and Company, Budapest, Hungary.
authors.forename: Tamas
authors.initials: T
authors.lastname: Treuer
keywords: Chinese; olanzapine; orally disintegrating; patients; schizophrenia